IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
Bai, Hua; Mao, Li; Wang, Hang Shu; Zhao, Jun; Yang, Lu; An, Tong Tong; Wang, Xin; Duan, Chun Jian; Wu, Na Mei; Guo, Zhi Qing; Liu, Yi Xu; Liu, Hong Ning; Wang, Ye Yu; Wang, Jie1
刊名JOURNAL OF CLINICAL ONCOLOGY
2009-06-01
DOI10.1200/JCO.2008.17.3930
27期:16页:2653-2659
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PREVIOUSLY TREATED PATIENTS ; SERUM DNA ; TYROSINE KINASE ; GENE-MUTATIONS ; GEFITINIB ; TRIAL ; COMBINATION ; INHIBITOR ; ERLOTINIB ; IRESSA
英文摘要

Purpose

Mutations in the epidermal growth factor receptor ( EGFR) kinase domain can predict tumor response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). However, obtaining tumor tissues for mutation analysis is challenging. We hypothesized that plasma-based EGFR mutation analysis is feasible and has value in predicting tumor response in patients with NSCLC.

Patients and Methods

Plasma DNA samples and matched tumors from 230 patients with stages IIIB to IV NSCLC were analyzed for EGFR mutations in exons 19 and 21 by using denaturing high-performance liquid chromatography. We compared the mutations in the plasma samples and the matched tumors and determined an association between EGFR mutation status and the patients′ clinical outcomes prospectively.

Results

In 230 patients, we detected 81 EGFR mutations in 79 (34.3%) of the patients′ plasma samples. We detected the same mutations in 63 (79.7%) of the matched tumors. Sixteen plasma (7.0%) and fourteen tumor (6.1%) samples showed unique mutations. The mutation frequencies were significantly higher in never-smokers and in patients with adenocarcinomas (P=.012 and P=.009, respectively). In the 102 patients who failed platinum-based treatment and who were treated with gefitinib, 22 (59.5%) of the 37 with EGFR mutations in the plasma samples, whereas only 15 (23.1%) of the 65 without EGFR mutations, achieved an objective response (P=.002). Patients with EGFR mutations had a significantly longer progression-free survival time than those without mutations (P=.044) in plasma.

Conclusion EGFR mutations can be reliably detected in plasma DNA of patients with stages IIIB to IV NSCLC and can be used as a biomarker to predict tumor response to TKIs. J Clin Oncol 27:2653-2659. (C) 2009 by American Society of Clinical Oncology

语种英语
WOS记录号WOS:000266454600015
引用统计
被引频次:205[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62982
专题北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Peking Univ, Sch Oncol, Dept Thorac Med Oncol, Beijing Canc Hosp & Inst, Beijing 100036, Peoples R China
2.Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
推荐引用方式
GB/T 7714
Bai, Hua,Mao, Li,Wang, Hang Shu,et al. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer[J]. JOURNAL OF CLINICAL ONCOLOGY,2009,27(16):2653-2659.
APA Bai, Hua.,Mao, Li.,Wang, Hang Shu.,Zhao, Jun.,Yang, Lu.,...&Wang, Jie.(2009).Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer.JOURNAL OF CLINICAL ONCOLOGY,27(16),2653-2659.
MLA Bai, Hua,et al."Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer".JOURNAL OF CLINICAL ONCOLOGY 27.16(2009):2653-2659.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Bai, Hua]的文章
[Mao, Li]的文章
[Wang, Hang Shu]的文章
百度学术
百度学术中相似的文章
[Bai, Hua]的文章
[Mao, Li]的文章
[Wang, Hang Shu]的文章
必应学术
必应学术中相似的文章
[Bai, Hua]的文章
[Mao, Li]的文章
[Wang, Hang Shu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。